Why Bio Plastic And Omega 3 Oils Are Set To Transform Your Food And Cosmetic Consumer Products
Make A Bio Degradable Difference
…Stop using single-use plastics.
…Help provide awareness to biodegradable and natural products.
…Be part of the solution to avoid destroying the planet.
…Don’t just make a change, make a difference.
…Omega 3 from heterotrophic fermentation of microalgae
…Optically pure lactic acid in biodegradable plastic PLA
…PHA/PHB extraction without the use of high-temperature solvents
…Any oilseed extraction process that currently uses solvents
…reducing some of the 300m tonnes of toxic plastic produced every year.
…the delivery of biodegradable plastic ingredients at close to petrochemical prices.
…lowering CO2 emissions from the food, cosmetic and bio-based industries.
…producing the lowest cost Omega-3 oil on the planet to counter over-fishing of our oceans.
Cellulac has developed and acquired, scientifically proven and commercially scaled technologies. These produce biodegradable products for the cosmetic, food, pharma and electronics industries. Market demand, for finished products in these industries, is $11bn p.a. This is forecast to grow at 19% p.a. until 2020.
- Bacteria 25%
- Process Engineering 50%
- Enzymatic Extraction 75%
- Commercial Production Site 100%
Game Changing - Operational Costs Savings
Commercial scale production of Omega 3, with EU and US clearance for human consumption. Produced since 2016 and guaranteed to lower your production costs by 24%.
Low CapEx Cost - Drop In Solution
When installed in your ethanol, dairy or brewing facilities they mitigate the high cost of capital, reduce your operational costs and improves net margins by adding complementary products.
Saves Energy, Reduces CO<sub>2</sub>
These unique low-pressure, low-temperature, wet extraction solutions use less energy, drastically cutting your costs, CO2 emissions and solvents for oil and biodegradable plastic ingredients.
egradable Plastic Production
History of Cellulac
In 2009 Patrick Walsh was a Professor at the National University of Galway, Ireland. His vision was to reduce the amount of energy in the production of biodegradable plastic. This biodegradable plastic ingredient is lactic acid. Used as a food preservative, curing agent, and flavoring agent. It is also an ingredient in processed foods, used during meat processing.
When broken down, the bio-degradable plastic ingredient converts back to CO2 and water.
Bacteria are easy to explain if you recall the 1984 and 1990 movie “Gremlins”. If you spilled water on them, they multiplied. Just like Gremlins, Lactic Acid and Micro-algae multiply in water.
2012 - New Management
By 2012 this small company, now named Cellulac, was €300,000 in debt, but had secured €2.8m of EU grants for a pilot plant, with the conditions for release of the grant be, that industry and investors had to contribute a further €9m.
New management were brought in. Even with the vision and the size of EU grant, finding €9 million for a pilot plant, that was never going to break-even, let alone be profitable, was equally never going to be built.
The team, which came from a previous successful company, Alltracel Pharmaceuticals, altered the direction and mission to address the glaring lack of infrastructure needed to commercialize the technology.
2013 - 1st Transaction
The first 25% of a low-cost production solution was achieved with Bacteria (read Gremlins). The conclusion of the acquisition of Pursuit Marine Drive meant that an end to end solution was now 50% completed.
There is a need to punch the living daylights out of the Gremlin-like bacteria and micro-algae. This begins the release of oils and bio-plastic polymer ingredients into a soup-like mixture.
Some of you will know the history of Pursuit Marine Drive. This was a former subsidiary of Pursuit Dynamix PLC (PDX). If so, you are probably wondering, why on earth did you buy a failed company that had blown through £68 million GBP. Right?
Well, the portion of £68m, spent in R&D, provided Cellulac with a unique game changing platform. This was the engineering equivalent of the Pfizer side-effect for their heart treatment, turned erectile dysfunctional drug, Viagra.
SoniqueFlo was originally designed as an industrial scale heat-exchanger that softened up grains before food, ethanol and beer production. Now, that same technology works 10 times more efficient. It smashes up softer cells on the recovery end of bio-oil and bio-plastic ingredient production.
It is like having millions of mini-Conor McGregors compressed into each SoniqueFlo reactor punching the oils and bio-plastic ingredient out of the Gremlin-like Bacteria and Micro-algae.
The beauty of this industrial scale solution is that the technology was already field tested. It has been fully operational in 25 production facilities across the food, bio-fuel and alcohol industries since 2010. This is where we get the benefit of having £68m spent before we acquired the technology.
2013 - 2nd Transaction
We reached the 75% milestone of full scale production when we secured access to the 2nd largest brewery in Ireland. This is 40 times the output and size of the Omega 3 at commercial scale plant in the UK since 2016.
It is the former Diageo, Harp Lager production plant in Dundalk, Ireland. A state-of-the-art facility, fully automated, food and beverage grade facility.
2015 - 3rd Transaction
The 100% scaled production milestone was reached in 2015, with the acquisition of Aer-Bio. This small Enzyme company specialized in the recovery of oils from micro-algae. More specifically in the production of Omega-3.
These (Pac-Man-like) enzymes are proteins that consume the outer layers of oil-bearing cells. Cellulac worked with Aer-Bio on a combination of the SoniqueFlo and Enzymes since early 2014. The result is a commercial scale low-carbon production solution for non-fish Omega-3 oils.
2016 - First Proven Commercial Scale Production
In 2016, at a UK industry partner site, a conventional high-carbon solvent process was removed. This was replaced by a solvent-free wet extraction process. The conversion resulted in an 81% reduction of the downstream recovery cost of Omega-3 oils. This represented a total reduction cost of Omega 3 oil by 24% per tonne.
The finished product has been granted approval as a human food grade product. The first sales of Omega-3 have been delivered to one of the largest food ingredient companies in the world.
2017 - 4th Transaction
In 2017 we agreed a 4th transaction. Our bio-plastic products will replace single-use plastic for medical, dental and cosmetic products.
Pharmafilter B.V. design, build and install self-contained energy recovery units in hospitals across Europe. They have agreed to purchase our bio-plastic for 5 hospitals each year, for the next 5 years. Hospitals use 600 tonnes of single-use plastic each year. Our bio-plastic reduces the carbon footprint of each hospital.
Our bio-degradable plastic is recycled by Pharmafilter, directly to gas. This gas-energy is burned to heat the hospitals and sterilize their waste water. It is a perfect example of the circular economy.
2018 - Ramp up of Scaled Production
The success of the commercial scale production of Omega 3 in 2016-2017 has been a significant milestone. 2018 will see the completion of the retrofit of the Cellulac production site in Ireland. After that we will ramp-up production to meet the offtake agreements for single use bio-plastics and Omega 3.
First full year production will be 2019.
Multiple MOU’s have been signed. Production and joint venture opportunities are open to Cellulac in Europe and the US. These are in the ethanol and dairy sectors. Licensing and royalty opportunities exist now we have demonstrated Omega-3 production at scale. This is the first, full scale game-changing, low-carbon production solution available for licensing.
Commercial Scale Production of Omega 3
Gerard is a seasoned international executive and serial entrepreneur, joining Cellulac as its CEO in May 2012. In 1996 he co-founded, as CEO, Alltracel Pharmaceuticals plc, which completed an IPO on AIM in 2001 and was subsequently acquired in 2008. In 2004 Gerard was appointed Managing Partner for Farmabrand Private Equity. He is an author and Fellow of the Ryan Academy of Entrepreneurs in DublinGerard Brandon
Camillus joined Cellulac as CFO in May 2012 and is a Chartered Accountant Institute member since 1985, qualifying with KPMG. He moved from his position as Operations Director at Campbell Bewley Group to be Chief of Operations at Alltracel Pharmaceuticals plc in 2003 and later stayed on after being acquired by Hemcon Medical Technologies as VP Global Business Development, 2009-2012.Camillus Glover
Marcus joined Cellulac in July 2013. He is the patent author and co-author of the SoniqueFlo technology and responsible for core process development. As well as being involved in the protection of the IP, he has overseen the development of integrated solutions for applications in the company’s production processes. He holds a BEng (Hons), MSc and PhD in Mechanical Engineering.Marcus Fenton
5-7 Cranwood Street, London EC1V 9EE, United Kingdom
Tel: +44 (0)1223 926 660